Free Republic

Pfizer’s antiviral oral drug developed to treat COVID-19 can cause severe or life-threatening effects when used with common medications including some anti-coagulants, some anti-depressants, and some cholesterol-lowering statins, according to the Food and Drug Administration (FDA) (pdf). FDA does not recommend Paxlovid for those with severe kidney or liver disease.The FDA on Dec. 22 granted emergency use authorization (EUA) to Pfizer’s COVID-19 treatment pill as treatment for mild-to-moderate cases of COVID-19 in patients from 12 years of age.Paxlovid was the first oral medication of its kind authorized by the FDA to treat COVID-19, with the aim of reducing the need...

The pro-drug industry mainstream media are insanely positive over the newly FDA-approved Pfizer antiviral COVID treatment pills. The drug, Paxlovid, received an emergency use authorization by FDA for use in patients 12 years old and up who have tested positive for COVID-19 and are at high risk.Now is the time to speak truth about Paxlovid. First, everyone should appreciate that there was very little testing of the short- and long-term safety of this product, exactly what happened with COVID vaccines. Really good testing of a new drug should take many months or even years.Does the public really want to take...

How good is the FDA at EUA approval for COVID drugs? Well, so far, to be honest, pretty shitty. The first three Covid drugs approved under EUA were Remdesivir, Baricitinib, and Tofacitinib. All were EUA approved for inpatient use (in hospital) only, demonstrate dismal effectiveness and are replete with black box warnings and side effects such as organ failure, blood clots, serious infections and malignancy. PAXLOVID PAXLOVID was recently approved by the FDA without any external meetings or disclosure. There was no opportunity for public input. Essentially all done behind closed doors. Dr. Ryan Cole on the drug’s mechanism of...

U.S. health regulators on Wednesday authorized the first pill against COVID-19, a Pfizer drug that Americans will be able to take at home to head off the worst effects of the virus. The oral drug, Paxlovid, is a faster, cheaper way to treat early COVID-19 infections, though initial supplies will be extremely limited. All of the previously authorized drugs against the disease require an IV or an injection. An antiviral pill from Merck also is expected to soon win authorization. But Pfizer's drug is all but certain to be the preferred option because of its mild side effects and superior...

An alarming admission was found near the bottom of a recent New York Times article about pharmaceutical giant Merck’s new Covid drug molnupiravir. Approved by the FDA two weeks ago, the drug was studied on isolated hamster cells for 32 days before being given the green light. While the FDA narrowly voted to recommend emergency use authorization for the drug, France’s National Authority of Health on Friday cited the pill’s own lack of efficacy as it ruled it will not be used in the European nation. According to the NYT report, “A team of researchers at the University of North...

Pfizer says testing on its planned COVID-19 treatment pill has shown it is effective against the omicron variant while also maintaining its efficacy in reducing hospitalizations and deaths caused by other variants. According to the Associated Press, a study conducted by Pfizer on 2,250 people showed the pill reduced combined hospitalizations and deaths by about 89% among high-risk adults who took the pill shortly after noticing COVID symptoms. Testing conducted by separate labs showed the treatment remained effective against the omicron variant, despite the pill being developed before omicron was spreading around the world. The treatment was tested against a...

Figure 1: A photo of a Pfizer facility in Italy. Image Source: Wikimedia Commons On November 5th, 2021, Pfizer announced that it would seek FDA approval for its new drug, called Paxlovid. It is given to those with an active case of COVID-19 and reduces the risk of hospitalization and death due to severe COVID-19 infections by 89% in a Phase 2/3 clinical trial (Pfizer, 2021). The drug consists of a combination of a SARS-CoV-2 (the virus that causes COVID-19) nsp5 inhibitor called PF-07321332 (see Figure 2, below) and an inhibitor of Cytochrome P450 3A4 (a human protein that often...

Pfizer announced Tuesday that a study found that its oral, antiviral COVID-19 pill Paxlovid reduced the risk of hospitalization or death by 89 percent in high-risk patients. Pfizer said that the 2,246 patients in the study were given the pill within three days of symptom onset, adding that they had mild to moderate symptoms as well as an underlying medical condition or an increased risk of becoming severely infected by COVID-19. The company said the results have been shared with the U.S. Food and Drug Administration (FDA) as a part of the company's request for emergency use authorization. Pfizer requested...

Merck’s antiviral pill for COVID-19, molnupiravir, appears to be far less effective than early results from the clinical trial first suggested.According to an analysis by scientists at the FDA, the experimental pill cut the risk of hospitalization or death from COVID-19 by about 30%, compared to a placebo, and the pill showed no benefit for people with antibodies against COVID-19 from prior infection.The updated analysis showed 48 hospitalizations or deaths among study participants who were randomly assigned to take the antiviral drug, compared to 68 among those who took a placebo.Those results come from the full set of 1,433 patients...

The Biden administration is expected to announce this week that it is purchasing 10 million courses of Pfizer’s covid pill, a multibillion-dollar investment in medication that officials hope will help change the trajectory of the pandemic by staving off many hospitalizations and deaths, according to two people with knowledge of the transaction. U.S. officials see this antiviral pill, and another by Merck and Ridgeback Biotherapeutics, as potential game-changers to help restore a broader sense of normalcy and are eager to add them to a small arsenal of treatments for Americans who contract the coronavirus. With breakthrough cases rising and 30...

(This is from Dr. Campbell's YouTube description) New Pfizer antiviral and ivermectin, a pharmacodynamic analysis New Pfizer antiviral, PF-07321332, C₂₃H₃₂F₃N₅O₄ PF-07321332 is designed to block the activity of the SARS-CoV-2-3CL protease,

Weird that two are “snake oil” and the expensive one will get EUA {Emergency Use Authorization by the FDA}

Video showing that Pfizers new anti-viral drug is virtually the same as Ivermectin. And interestingly they have research that their version of ivermectin works against COVID but they have no research that the real ivermectin works. Of course the real Ivermectin costs 10 cents a pill outside the US.

An experimental pill to treat Covid developed by the US company Pfizer cuts the risk of hospitalisation or death by 89% in vulnerable adults, clinical trial results suggest. The drug - Paxlovid - is intended for use soon after symptoms develop in people at high risk of severe disease. . . . . Interim data from trials of the treatment in 1,219 high-risk patients who had recently been infected with Covid found that 0.8% of those given Paxlovid were hospitalised compared with 7% of patients who were given a placebo or dummy pill. They were treated within three days of...